Replies to post #42749 on Anavex Life Sciences Corp (AVXL)

[colmar]

AVXL - those are really incredible results, thx for posting. Potential here is almost unreal.

[stealthways]

"I would bet money that ANAVEX will be doing Phase-2 trials in 2016 for both Epilepsy and Parkinsons. Besides a Phase-3 for Alzheimers with Anavex 2-73!! Think about how much that will impact share price. Great times around the corner!!"...SA commentor

and add to the above progress on 371.......

[oneflew12]

Wolf thanks this sounds like our drug really can help, and Monday we should get great news .

[blanka]

Science is Great but let's see who is:

Corinne Lasmézas, DVM, PhD

On AVXL Website it states:

KEY POINTS TO CONFIRM...???

Corinne Lasmézas, DVM, PhD

A member of the Scientific Advisory Board, Professor at The Scripps Research Institute for the past 10 years and frequent TED Speaker, Dr. Lasmézas is an internationally recognized expert in the field of neurodegenerative diseases with a focus now on studying the mechanisms of neurodegeneration. Since her appointment at Scripps in 2005, Dr. Lasmézas has focused on how misfolded proteins lead to neuronal dysfunction and loss in diseases including Alzheimer’s, Parkinson’s and prion diseases. Additionally, Dr. Lasmézas is a reviewer for national and private funding agencies worldwide, including the US National Institutes of Health (NIH) and the UK Medical Research Council, and an advisor for the US Food and Drug Administration (FDA), the US Environmental Protection Agency (EPA) and the US Department of Agriculture (USDA). She has published more than 60 original scientific papers. Earlier in her career, Dr. Lasmézas’ research provided the first experimental evidence that the prion disease “mad cow disease” had been transmitted to humans, causing variant Creutzfeldt-Jakob disease. This fatal disease belongs to the same group of age-related neurodegenerative diseases as Alzheimer and Parkinson’s diseases, caused by aggregates of misfolded proteins. At the peak of the mad cow crisis, Dr. Lasmézas became an advisor to the World Health Organization (WHO) as well as several governmental and public health committees. Dr. Lasmézas holds a PhD in Neurosciences from the University Pierre & Marie Curie in Paris and obtained her Doctorate of Veterinary Medicine and Diploma of Aeronautic and Space Medicine from the University of Toulouse, France.

AVXL

[frrol]

I think that 2-73 and 3-71 will be breakthrough drugs in the literal, if not regulatory, definition of the term. The potential adjunctive applications in the preclinical (and for 2-73, the clinical) results are exciting stuff. AD and epilepsy? Huge needs. Patience and hope.